Little is known about somathormone (GH) secretion in hyperthyroidism: plasma GH levels may be enhanced (Ortigosa, Mendoza, Argote, Garcia, Cervantes andParra 1976); abnormal response to oral glucose or insulin hypoglycemia may be observed (Cavagnini, Peracepi, Raggi, Bana, Ponttroli, Malinverni and Pinto 1974). However, hyperthyroidism is a putative state of sympathetic overactivity (Karlberg, Henriksson and Andersson 1974) and the a-adrenergic system is believed to participate in the regulation of GH secretion in animals and human beings {Lancranjan znAMarbach 1977; Terry and Martin 1981).
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Beta-blockers are widely used in hyperthyroidism. If effects on cardiovascular manifestations have been extensively studied, less is known about endocrine effects. Furthermore, they may differ according to the drug pharmacological properties. With regard to GH secretion, we are only aware of a slight increase of GH response to insulin hypoglycemia in hyperthyroid patients pretreated with propranolol, that is not observed in those pretreated with metoprolol (Nilsson, Anderberg, Karlberg and Kagedal 1980) . These observations, with the fact that the regulation of carbohydrate metabolism is frequently disturbed in hyperthyroidism, inspired the present study, which compared the effects of 2 beta-blockers on GH response to oral glucose in patients with untreated hyperthyroidism. The patients received either propranolol, a non selective beta-blocking drug, or betaxolol, a potent and selective beta 1 -adrenoreceptor antagonist.
Material and Methods
Twenty-one untreated hyperthyroid patients, aged from 18 to 60 (mean 40.8±4.6), were studied under single-blind conditions and randomly allocated to two treatment groups: nine were treated with long-acting propranolol (ICI-Pharma, Enghein, France) at a starting daily dose of 160 mg; twelve received betaxolol (Robert et Carriere/Synthelabo, Paris, France) at a starting daily dose of 20 mg. An oral glucose tolerance test (OGTT: 75 g of glucose) was performed before and 3 to 5 days after starting the treatment. This time lapse was designed so that the post-treatment OGTT followed a reduction in the heart rate either to 80 beats/minute or less or to a level at least 20 per cent lower than the baseline heart rate. This required, if necessary, an increase of drug dosage. The blood glucose and GH levels, their peak concentrations, times to peak and areas under the concentration/time curses were determined. The plasma beta-blocker concentration was determined at time zero of the second OGTT, 2 to 5 hours after administration. The results were compared with those obtained in healthy controls. The control and the treated groups were comparable in terms of their sex ratio, age, body weight and, among patients, duration and severity of hyperthyroidism. Glucose was measured by a standard automated technique. GH was measured by a commercial radio-immunoassay kit. Propranolol was assayed by high-performance liquid chromatography using fluorescence detection. Betaxolol was assayed by a specific gas chromatographic method (Bianchetti, Ganansia and Morselli 1979) . Results are expressed as means±l S.E.M. of the mean value. The intra-group differences were tested by the Student's t-test. Intergroup differences were tested by one-way analysis of covariance with respect to baseline values.
Results and Discussion
For the following parameters -blood levels of glucose and GH, peak concentrations, times to peak and areas under the concentration/time curves, no significant intra-group or inter-group difference was detected. Data regarding GH secretion are only mentioned (Table 1) . Plasma beta-blocker concentrations were above the optimal therapeutic level two times with propranolol, one time with betaxolol.
At least with this methodology, it appears that beta-blockade, either selective or non-selective does not modify GH secretion during OGTT in hyperthyroid patients. It may be also inferred that an abnormability of GH secretion is probably not involved in the glucose intolerance frequently encountered is this endocrinopathy (Kabadi and Elsenstein 1980) .
